Glaxo’s Votrient Gains U.S. Approval for Deadly Sarcomas

GlaxoSmithKline Plc won U.S. clearance to expand marketing of its 2-year-old kidney-cancer pill Votrient for rare malignancies known as soft-tissue sarcomas.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.